Variable Absorption of Carbidopa Affects Both Peripheral and Central Levodopa Metabolism
Autor: | Raymon Durso, Barbara A. Evans, Thomas R. Browne, Ephraim G. Josephs, H. H. Fernandez, George K. Szabo, James E. Evans |
---|---|
Rok vydání: | 2000 |
Předmět: |
Adult
medicine.medical_specialty Levodopa Carboxy-lyases Absorption Antiparkinson Agents Cerebrospinal fluid Bolus (medicine) Pharmacokinetics Internal medicine medicine Humans Pharmacology (medical) Child Aged Pharmacology Chemistry Area under the curve Brain Carbidopa Homovanillic Acid Middle Aged Peripheral Endocrinology medicine.drug |
Zdroj: | The Journal of Clinical Pharmacology. 40:854-860 |
ISSN: | 0091-2700 |
DOI: | 10.1177/00912700022009585 |
Popis: | Carbidopa (CD), a competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine. Using a stable isotope-labeled form of LD, the authors examined in 9 PD patients the effects of variable CD absorption on peripheral and central LD metabolism. Subjects were administered orally 50 mg of CD followed in 1 hour by a slow bolus intravenous infusion of 150 mg stable isotope-labeled LD (ring 1',2',3',4',5',6'-13C). Eight patients underwent a lumbar puncture 6 hours following the infusion. Blood and cerebrospinal fluid (CSF) samples were analyzed for labeled and unlabeled metabolites using a combination of high-performance liquid chromatography and mass spectrometry. When patients were divided into "slow" and "rapid" CD absorption groups, significantly greater peripheral LD decarboxylation (as measured by area under the curve [AUC]-labeled serum HVA) was noted in the poor absorbers (p = 0.05, Mann-Whitney U test). Elimination half-lives for serum LD did not differ between groups, suggesting a further capacity for decarboxylation inhibition in the "rapid" absorbers. A significant correlation between AUC serum CD and percent-labeled HVA in CSF was found for all patients (R = 0.786, p = 0.02). "Rapid" as compared to "slow" CD absorbers had significantly more percent-labeled CSF HVA (60 vs. 49, p = 0.02, Mann-Whitney U test), indicating greater central-labeled DA production in the better CD absorbers. The data suggest that peripheral aromatic l-amino acid decarboxylase activity is not saturated at CD doses used in current practice. The authors believe that future studies to better examine a dose dependence of CD on peripheral LD decarboxylation and LD brain uptake are warranted. |
Databáze: | OpenAIRE |
Externí odkaz: |